2002 Fiscal Year Final Research Report Summary
Establishment of Prevention and Treatment for Development of Atherosclerosis by regulation of Lipocalin-Type Prostaglandin D Synthase
Project/Area Number |
13670705
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Circulatory organs internal medicine
|
Research Institution | Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science |
Principal Investigator |
MATSUMOTO Tetsuya Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, 医学部, 助手 (70273406)
|
Co-Investigator(Kenkyū-buntansha) |
EGUCHI Naomi Osaka Bioscience Institute, Department of Molecular Behavioral Biology, 第2研究部, 副部長 (10250086)
TORII Ryuzo Shiga University of Medical Science, Research Center for Animal Life Science, 動物生命科学研究センター, 教授 (50106647)
URADE Yoshihiro Osaka Bioscience Institute, 第2研究部, 研究部長 (10201360)
EGUCHI Yutaka Shiga University of Medical Science, Intensive Care Unit, 医学部, 講師 (00263054)
|
Project Period (FY) |
2001 – 2002
|
Keywords | Prostaglandin D2 / Atherosclerosis / Coronary artery / Smooth muscle |
Research Abstract |
Lipocalin-type prostaglandin (PG) D synthase (L-PGDS), which is responsible for the biosynthesis of PGD2, has recently been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. L-PGDS is one of the enzymes that catalyze PGD2 synthesis, and so we speculate that PGD2 synthesis mediated by L-PGDS is related to pathogenesis of atherosclerosis. Considering the roles of L-PGDS in the pathophysiology of coronary artery disease, it is suggested that L-PGDS generation in the atherosclerotic plaques has an anti-atherogenic effect. Furthermore, we observed the immunoreactivity and mRNA expression of L-PGDS to confirm that L-PGDS was definitely localized and generated in atherosclerotic plaques, especially in these in the human and monkey coronary artery. The major findings are that serum L-PGDS level was elevated in patients with coronary artery disease and that the level increased in association with the number of affected vessels (Teruo inoue, Yutaka Eguchi, Tetsuya Matsumoto, Yoshihiro Urade et al. Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of coronary artery disease, submitted). The serum L-PGDS level may be suitable to evaluate the severity of coronary artery disease. It is concluded that the measurement of serum L-PGDS can be a strategy for screening of coronary artery disease prior to coronary angiography.
|
Research Products
(14 results)
-
-
-
-
-
-
-
-
-
-
-
[Publications] Tsutamoto T, Wada A, Matsumoto T, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Yamamoto T, Horie H, Sugimoto Y, Kinoshita M.: "Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy"J Am Coll Cardiol.. 37(8). 2086-2092 (2001)
Description
「研究成果報告書概要(欧文)」より
-
-
-